{"id":6665,"date":"2025-10-29T09:46:38","date_gmt":"2025-10-29T02:46:38","guid":{"rendered":"https:\/\/regular-investor.com\/?p=6665"},"modified":"2025-10-29T09:46:43","modified_gmt":"2025-10-29T02:46:43","slug":"kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi","status":"publish","type":"post","link":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/","title":{"rendered":"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Kinerja Keuangan Kalbe Farma Tbk September 2025<\/h3>\n\n\n\n<p>PT Kalbe Farma Tbk (KLBF) mencatatkan kinerja keuangan yang solid sepanjang sembilan bulan pertama tahun 2025. Laba bersih tercatat tumbuh 10,6% secara tahunan (YoY) menjadi Rp 2,6 triliun. Pertumbuhan ini didorong oleh peningkatan penjualan bersih sebesar 7,2% YoY menjadi Rp 26 triliun, serta perbaikan margin laba kotor dan efisiensi operasional.<\/p>\n\n\n\n<p>Dalam laporan keuangan konsolidasian tidak diaudit per 30 September 2025, Kalbe menyoroti kontribusi utama dari segmen:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Obat Resep<\/strong><\/li>\n\n\n\n<li><strong>Produk Kesehatan<\/strong><\/li>\n\n\n\n<li><strong>Distribusi dan Logistik<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Margin laba kotor meningkat menjadi 40,6%, naik dari periode yang sama tahun lalu. Hal ini dipengaruhi oleh bauran produk yang lebih menguntungkan dan stabilnya harga bahan baku.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pernyataan Manajemen: Optimisme di Tengah Gejolak Global<\/h3>\n\n\n\n<p>Presiden Direktur Kalbe Farma, Irawati Setiady, menyampaikan bahwa perusahaan berhasil menjaga momentum pertumbuhan meski menghadapi tantangan ekonomi global.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cBerbagai inisiatif strategis seperti ekosistem onkologi, pengembangan obat biologis dan alat kesehatan berjalan sesuai rencana. Kami juga melanjutkan rejuvenasi brand agar tetap relevan dengan tren konsumen,\u201d ujar Irawati, dikutip Selasa (28\/10\/2025).<\/p>\n<\/blockquote>\n\n\n\n<p>Kalbe juga menegaskan komitmen terhadap kemandirian kesehatan nasional dan optimisme terhadap peluang industri farmasi Indonesia.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Divisi-Divisi Penopang Kinerja Kalbe<\/h3>\n\n\n\n<p>Berikut rincian kinerja masing-masing divisi:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Divisi<\/th><th>Pertumbuhan YoY<\/th><th>Sorotan Utama<\/th><\/tr><\/thead><tbody><tr><td>Obat Resep<\/td><td>+11,0%<\/td><td>Produk specialty, generik JKN, ekspansi Asia Tenggara<\/td><\/tr><tr><td>Produk Kesehatan<\/td><td>+9,4%<\/td><td>Rejuvenasi merek, pengembangan produk preventif<\/td><\/tr><tr><td>Nutrisi<\/td><td>-2,1%<\/td><td>Daya beli lemah, fokus pada produk sehat dan terjangkau<\/td><\/tr><tr><td>Distribusi &amp; Logistik<\/td><td>+10,3%<\/td><td>Produk eksternal, alat kesehatan lokal sebagai sumber pertumbuhan berkelanjutan<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Komitmen terhadap Pemegang Saham<\/h3>\n\n\n\n<p>Kalbe meningkatkan rasio pembayaran dividen menjadi 50\u201360% dari laba bersih. Selain itu, perusahaan melanjutkan program pembelian kembali saham senilai Rp 250 miliar, setelah sebelumnya merealisasikan Rp 1,25 triliun.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Strategi dan Prospek Kalbe di Sisa 2025<\/h3>\n\n\n\n<p>Menghadapi risiko geopolitik dan fluktuasi ekonomi global, Kalbe menekankan strategi berikut:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Digitalisasi proses bisnis<\/li>\n\n\n\n<li>Efisiensi rantai pasok<\/li>\n\n\n\n<li>Pengelolaan risiko mata uang asing<\/li>\n\n\n\n<li>Efektivitas pemasaran<\/li>\n<\/ul>\n\n\n\n<p>Dengan arus kas yang sehat, Kalbe optimis mencapai target pertumbuhan penjualan dan laba bersih di kisaran 6\u20138% untuk tahun 2025.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kinerja Keuangan Kalbe Farma Tbk September 2025 PT Kalbe Farma Tbk (KLBF) mencatatkan kinerja keuangan yang solid sepanjang sembilan bulan pertama tahun 2025. Laba bersih tercatat tumbuh 10,6% secara tahunan (YoY) menjadi Rp 2,6 triliun. Pertumbuhan ini didorong oleh peningkatan penjualan bersih sebesar 7,2% YoY menjadi Rp 26 triliun, serta perbaikan margin laba kotor dan [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":6667,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_links_to":"","_links_to_target":""},"categories":[288],"tags":[2998,2697,4674,4675,2696],"class_list":["post-6665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-kinerja-keuangan","tag-klbf","tag-laba-bersih-2025","tag-penjualan-kalbe-farma","tag-pt-kalbe-farma-tbk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi - Regular-investor.com<\/title>\n<meta name=\"description\" content=\"PT Kalbe Farma Tbk (KLBF) membukukan laba bersih Rp 2,6 triliun hingga September 2025, tumbuh 10,6% YoY. Kinerja ditopang segmen Obat Resep, Produk Kesehatan, dan Distribusi. Simak strategi dan prospek Kalbe ke depan.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi - Regular-investor.com\" \/>\n<meta property=\"og:description\" content=\"PT Kalbe Farma Tbk (KLBF) membukukan laba bersih Rp 2,6 triliun hingga September 2025, tumbuh 10,6% YoY. Kinerja ditopang segmen Obat Resep, Produk Kesehatan, dan Distribusi. Simak strategi dan prospek Kalbe ke depan.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/\" \/>\n<meta property=\"og:site_name\" content=\"Regular-investor.com\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/regularinvestorscom\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-29T02:46:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T02:46:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/10\/Kalbe-Farma.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"690\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Septian\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@rinvestorcom\" \/>\n<meta name=\"twitter:site\" content=\"@rinvestorcom\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Septian\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/\"},\"author\":{\"name\":\"Septian\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/person\\\/e0935cf1dd7abe3c6dc3ba60c4c6afbf\"},\"headline\":\"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi\",\"datePublished\":\"2025-10-29T02:46:38+00:00\",\"dateModified\":\"2025-10-29T02:46:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/\"},\"wordCount\":313,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Kalbe-Farma.webp\",\"keywords\":[\"Kinerja Keuangan\",\"KLBF\",\"Laba Bersih 2025\",\"Penjualan Kalbe Farma\",\"PT Kalbe Farma Tbk\"],\"articleSection\":[\"Market\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/\",\"name\":\"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi - Regular-investor.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Kalbe-Farma.webp\",\"datePublished\":\"2025-10-29T02:46:38+00:00\",\"dateModified\":\"2025-10-29T02:46:43+00:00\",\"description\":\"PT Kalbe Farma Tbk (KLBF) membukukan laba bersih Rp 2,6 triliun hingga September 2025, tumbuh 10,6% YoY. Kinerja ditopang segmen Obat Resep, Produk Kesehatan, dan Distribusi. Simak strategi dan prospek Kalbe ke depan.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Kalbe-Farma.webp\",\"contentUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Kalbe-Farma.webp\",\"width\":1080,\"height\":690},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/10\\\/29\\\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/regular-investor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#website\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/\",\"name\":\"Regular-investor.com\",\"description\":\"You Sleep and Makes Money\",\"publisher\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#organization\"},\"alternateName\":\"R-INVESTOR\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regular-investor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#organization\",\"name\":\"Regular-investor.com\",\"alternateName\":\"R-INVESTOR\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/cropped-Photoroom-20250309_055542.png\",\"contentUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/cropped-Photoroom-20250309_055542.png\",\"width\":512,\"height\":512,\"caption\":\"Regular-investor.com\"},\"image\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/regularinvestorscom\",\"https:\\\/\\\/x.com\\\/rinvestorcom\",\"https:\\\/\\\/www.instagram.com\\\/regularinvestorcom\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/person\\\/e0935cf1dd7abe3c6dc3ba60c4c6afbf\",\"name\":\"Septian\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g\",\"caption\":\"Septian\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi - Regular-investor.com","description":"PT Kalbe Farma Tbk (KLBF) membukukan laba bersih Rp 2,6 triliun hingga September 2025, tumbuh 10,6% YoY. Kinerja ditopang segmen Obat Resep, Produk Kesehatan, dan Distribusi. Simak strategi dan prospek Kalbe ke depan.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/","og_locale":"en_US","og_type":"article","og_title":"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi - Regular-investor.com","og_description":"PT Kalbe Farma Tbk (KLBF) membukukan laba bersih Rp 2,6 triliun hingga September 2025, tumbuh 10,6% YoY. Kinerja ditopang segmen Obat Resep, Produk Kesehatan, dan Distribusi. Simak strategi dan prospek Kalbe ke depan.","og_url":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/","og_site_name":"Regular-investor.com","article_publisher":"https:\/\/facebook.com\/regularinvestorscom","article_published_time":"2025-10-29T02:46:38+00:00","article_modified_time":"2025-10-29T02:46:43+00:00","og_image":[{"width":1080,"height":690,"url":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/10\/Kalbe-Farma.webp","type":"image\/webp"}],"author":"Septian","twitter_card":"summary_large_image","twitter_creator":"@rinvestorcom","twitter_site":"@rinvestorcom","twitter_misc":{"Written by":"Septian","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#article","isPartOf":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/"},"author":{"name":"Septian","@id":"https:\/\/regular-investor.com\/#\/schema\/person\/e0935cf1dd7abe3c6dc3ba60c4c6afbf"},"headline":"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi","datePublished":"2025-10-29T02:46:38+00:00","dateModified":"2025-10-29T02:46:43+00:00","mainEntityOfPage":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/"},"wordCount":313,"commentCount":0,"publisher":{"@id":"https:\/\/regular-investor.com\/#organization"},"image":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#primaryimage"},"thumbnailUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/10\/Kalbe-Farma.webp","keywords":["Kinerja Keuangan","KLBF","Laba Bersih 2025","Penjualan Kalbe Farma","PT Kalbe Farma Tbk"],"articleSection":["Market"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/","url":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/","name":"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi - Regular-investor.com","isPartOf":{"@id":"https:\/\/regular-investor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#primaryimage"},"image":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#primaryimage"},"thumbnailUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/10\/Kalbe-Farma.webp","datePublished":"2025-10-29T02:46:38+00:00","dateModified":"2025-10-29T02:46:43+00:00","description":"PT Kalbe Farma Tbk (KLBF) membukukan laba bersih Rp 2,6 triliun hingga September 2025, tumbuh 10,6% YoY. Kinerja ditopang segmen Obat Resep, Produk Kesehatan, dan Distribusi. Simak strategi dan prospek Kalbe ke depan.","breadcrumb":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#primaryimage","url":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/10\/Kalbe-Farma.webp","contentUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/10\/Kalbe-Farma.webp","width":1080,"height":690},{"@type":"BreadcrumbList","@id":"https:\/\/regular-investor.com\/index.php\/2025\/10\/29\/kalbe-farma-catat-laba-bersih-rp-26-triliun-di-kuartal-iii-2025-fokus-pada-inovasi-dan-efisiensi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/regular-investor.com\/"},{"@type":"ListItem","position":2,"name":"Kalbe Farma Catat Laba Bersih Rp 2,6 Triliun di Kuartal III 2025, Fokus pada Inovasi dan Efisiensi"}]},{"@type":"WebSite","@id":"https:\/\/regular-investor.com\/#website","url":"https:\/\/regular-investor.com\/","name":"Regular-investor.com","description":"You Sleep and Makes Money","publisher":{"@id":"https:\/\/regular-investor.com\/#organization"},"alternateName":"R-INVESTOR","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regular-investor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/regular-investor.com\/#organization","name":"Regular-investor.com","alternateName":"R-INVESTOR","url":"https:\/\/regular-investor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/regular-investor.com\/#\/schema\/logo\/image\/","url":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/03\/cropped-Photoroom-20250309_055542.png","contentUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/03\/cropped-Photoroom-20250309_055542.png","width":512,"height":512,"caption":"Regular-investor.com"},"image":{"@id":"https:\/\/regular-investor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/regularinvestorscom","https:\/\/x.com\/rinvestorcom","https:\/\/www.instagram.com\/regularinvestorcom\/"]},{"@type":"Person","@id":"https:\/\/regular-investor.com\/#\/schema\/person\/e0935cf1dd7abe3c6dc3ba60c4c6afbf","name":"Septian","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g","caption":"Septian"}}]}},"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts\/6665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/comments?post=6665"}],"version-history":[{"count":1,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts\/6665\/revisions"}],"predecessor-version":[{"id":6668,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts\/6665\/revisions\/6668"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/media\/6667"}],"wp:attachment":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/media?parent=6665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/categories?post=6665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/tags?post=6665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}